The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics around the investing world.

In today's edition, David discusses the recent developments surrounding GlaxoSmithKline's offer for Human Genome Sciences. Shares sit right between their 52-week high and low, but David urges investors not to get greedy. A new poison pill has Glaxo upset, and if the big pharma walks, how will that affect Human Genome Sciences' investors? Watch and find out.

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.